Palliative Care and Symptom Management in Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Scientific Articles

Palliative Care and Symptom Management in Amyloidosis

key information

source: Current Problems in Cancer

year: 2016

authors: Tsukanov J, Fabbro ED

summary/abstract:

The World Health Organization definition of palliative care (PC) declares that PC may be incorporated into the management of any patient with a life-limiting illness, whether early in the illness trajectory in conjunction with disease-specific therapies, or at the end of life. This concept of simultaneous care is underscored by an integrated model1 of PC in combination with oncologic care, a model supported by the American Society of Clinical Oncology (ASCO), and an important element of ASCO’s vision for achieving comprehensive cancer care. Light chain amyloidosis (AL), the most common form of systemic amyloidosis, is characterized by the production of light chain proteins by abnormal plasma cells. 

The deposition and accumulation of proteins in various organs cause injury and produce symptoms. However, similarly to patients with cancer, symptoms may be because of the disease process or the treatment, and can include fatigue, weakness, dyspnea, pain, dizziness, anorexia, cachexia, edema, diarrhea, and constipation. The degree of symptom burden, timing of onset, and location of affected areas vary among patients and although the initial site of presentation is unpredictable; a dominant site is often identifiable. 

organization: Virginia Commonwealth University, USA

DOI: 10.1016/j.currproblcancer.2016.09.006

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close